Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-05-14

New possibilities for accessing the capital markets for small and medium-sized biotech enterprises

Objectif



Because of the necessary high R&D investments and the costly market introduction and diffusion of biotechnology products (especially in the health care sector), small and medium-sized enterprises (SMEs) in the biotechnology area face specific problems in financing their business activities. In most Member States of the EU investments by venture capital companies in biotechnology are rather limited. As one reason for this fact investment managers primarily note the missing of a specific segment on the European stock market where shares of technology based SMEs are quoted. For this reason venture capital and other investment companies have some difficulties to find an adequate exit possibility if they intend to sell their investments in biotech companies via the stock exchange.
Since a few years several stock exchange markets in Europe lower the requirements for the listing of small and medium technology-based companies. In this context the London stock exchange has taken the leadership by amending the rules for entry to the official list in 1993 and the opening of the Alternative Investment Market (AIM) in 1995. In addition, "Le Nouveau Marché" opened for business on the stock exchange in Paris in February 1996. On the stock exchange in Frankfurt/Main a so-called "Neuer Markt" is planned for 1997 in which start-up or R&D intensive high-tech companies shall achieve a listing. In addition, a European pendant to the US NASDAQ located in Brussels was scheduled to open at the end of 1996 (EASDAQ).
Therefore, a study is proposed which will systematically collect, analyse and critically evaluate the experience of biotechnology SMEs and investment companies which have already tried to go public on one of the above mentioned markets. In addition, it will be analysed under which circumstances the new or planned possibilities are used from investors and biotech companies. Recommendations on the practical implementation of these results will be worked out covering successful investment strategies and their prerequisites, requirements and measures taken to achieve a successful listing on a stock exchange and existing constraints or gaps in the current possibilities on these markets. The results of the study will be especially beneficial for SMEs which need funding for their business activities but lack the experience and the resources in developing appropriate investment strategies on their own. The study will be fruitful for investors as well who want to optimise their profits in the biotechnology field in the long-term.
Thus, the proposed study will contribute to reducing the financing barriers existing for European biotech companies, improving the financing possibilities of these companies and extending the exit possibilities of potential investors. These activities are regarded as crucial in order to fully exploit the possibilities of biotechnology in the European economy.

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: Le vocabulaire scientifique européen.

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Programme(s)

Programmes de financement pluriannuels qui définissent les priorités de l’UE en matière de recherche et d’innovation.

Thème(s)

Les appels à propositions sont divisés en thèmes. Un thème définit un sujet ou un domaine spécifique dans le cadre duquel les candidats peuvent soumettre des propositions. La description d’un thème comprend sa portée spécifique et l’impact attendu du projet financé.

Appel à propositions

Procédure par laquelle les candidats sont invités à soumettre des propositions de projet en vue de bénéficier d’un financement de l’UE.

Données non disponibles

Régime de financement

Régime de financement (ou «type d’action») à l’intérieur d’un programme présentant des caractéristiques communes. Le régime de financement précise le champ d’application de ce qui est financé, le taux de remboursement, les critères d’évaluation spécifiques pour bénéficier du financement et les formes simplifiées de couverture des coûts, telles que les montants forfaitaires.

CSC - Cost-sharing contracts

Coordinateur

FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Contribution de l’UE
Aucune donnée
Adresse
Breslauer Strasse 48
76139 Karlsruhe
Allemagne

Voir sur la carte

Coût total

Les coûts totaux encourus par l’organisation concernée pour participer au projet, y compris les coûts directs et indirects. Ce montant est un sous-ensemble du budget global du projet.

Aucune donnée

Participants (1)

Mon livret 0 0